We are live on
!
Find out more
Arrowstreet Capital Portfolio holdings
AUM
$185B
1-Year Est. Return
39.58%
This Fund
S&P 500
This Quarter
Est. Return
+10.23%
1 Year Est. Return
+39.58%
3 Year Est. Return
+145.48%
5 Year Est. Return
+192.07%
10 Year Est. Return
+749.68%
AUM
$43B
AUM Growth
+$121M
(+0.28%)
Cap. Flow
-$3.21B
Cap. Flow
% of AUM
-7.47%
Top 10 Holdings %
Top 10 Hldgs %
18.86%
Holding
2,029
New
505
Increased
717
Reduced
446
Closed
331
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Intel
INTC
|
+$285M |
| 2 |
Applied Materials
AMAT
|
+$234M |
| 3 |
Micron Technology
MU
|
+$185M |
| 4 |
Merck
MRK
|
+$161M |
| 5 |
NXP Semiconductors
NXPI
|
+$152M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CELG
Celgene Corp
CELG
|
+$505M |
| 2 |
Bank of America
BAC
|
+$339M |
| 3 |
Nike
NKE
|
+$335M |
| 4 |
Union Pacific
UNP
|
+$329M |
| 5 |
Citigroup
C
|
+$277M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 23.49% |
| 2 | Financials | 16.82% |
| 3 | Consumer Discretionary | 16.55% |
| 4 | Healthcare | 14.39% |
| 5 | Industrials | 8.67% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1351
T. Rowe Price
TROW
$24.3B
| $947K | ﹤0.01% |
+7,776
| New | +$918K |
|
1352
BRC Group Holdings
RILY
$289M
| $942K | ﹤0.01% |
+37,396
| New | +$984K |
|
1353
Amneal Pharmaceuticals
AMRX
$5.79B
| $934K | ﹤0.01% |
+193,736
| New | +$673K |
|
|
MRC
1354
DELISTED
MRC Global
MRC
| $934K | ﹤0.01% |
+68,500
| New | +$893K |
|
1355
Construction Partners
ROAD
$6.77B
| $930K | ﹤0.01% |
55,104
+19,304
| +54% | +$339K |
|
|
PRFT
1356
DELISTED
Perficient Inc
PRFT
| $927K | ﹤0.01% |
+20,123
| New | +$820K |
|
1357
Fortuna Silver Mines
FSM
$3.07B
| $926K | ﹤0.01% |
227,300
-681,734
| -75% | -$2.23M |
|
|
YJ
1358
Yunji
YJ
$16.7M
| $924K | ﹤0.01% |
+5,041
| New | +$1.04M |
|
1359
Westwood Holdings Group
WHG
$190M
| $919K | ﹤0.01% |
31,031
-3,464
| -10% | -$103K |
|
1360
Danaos Corp
DAC
$2.56B
| $913K | ﹤0.01% |
+99,415
| New | +$960K |
|
1361
LSI Industries
LYTS
$924M
| $912K | ﹤0.01% |
150,786
+63,192
| +72% | +$348K |
|
1362
TORM
TRMD
$3.02B
| $912K | ﹤0.01% |
+81,545
| New | +$775K |
|
1363
Dime Commercial Bancshares
DCOM
$1.78B
| $899K | ﹤0.01% |
+26,814
| New | +$861K |
|
1364
Quad
QUAD
$525M
| $893K | ﹤0.01% |
+191,275
| New | +$1.2M |
|
1365
MGP Ingredients
MGPI
$375M
| $890K | ﹤0.01% |
+18,371
| New | +$860K |
|
|
MODV
1366
DELISTED
ModivCare
MODV
| $889K | ﹤0.01% |
+15,025
| New | +$917K |
|
|
AVX
1367
DELISTED
AVX Corporation
AVX
| $889K | ﹤0.01% |
+43,447
| New | +$748K |
|
|
JCP
1368
DELISTED
J.C. Penney Company, Inc.
JCP
| $884K | ﹤0.01% |
788,901
+78,622
| +11% | +$83.5K |
|
1369
WPP
WPP
$5.94B
| $881K | ﹤0.01% |
+12,538
| New | +$795K |
|
1370
Labcorp
LH
$25.9B
| $880K | ﹤0.01% |
+6,053
| New | +$874K |
|
|
TRQ
1371
DELISTED
Turquoise Hill Resources Ltd
TRQ
| $873K | ﹤0.01% |
118,603
-101,537
| -46% | -$522K |
|
1372
Leggett & Platt
LEG
$1.31B
| $869K | ﹤0.01% |
+17,100
| New | +$838K |
|
1373
Takeda Pharmaceutical
TAK
$55.7B
| $866K | ﹤0.01% |
+43,883
| New | +$840K |
|
1374
Wintrust Financial
WTFC
$10.7B
| $865K | ﹤0.01% |
12,200
-2,600
| -18% | -$173K |
|
1375
Mitek Systems
MITK
$834M
| $863K | ﹤0.01% |
+112,759
| New | +$951K |
|
Similar funds
VGA
Arrowstreet Capital's Q4 2019 Portfolio in Review
As of Q4 2019, Arrowstreet Capital held 2,029 positions worth $43B, up 0.28% from $42.9B the previous quarter. Its ten largest holdings account for 19% of the portfolio.
Arrowstreet Capital withdrew a net $3.21B in Q4 2019, closing 331 positions and reducing 446 holdings. Its most notable exit was Celgene Corp, an estimated $505M position sold in full.
By sector, the portfolio is most concentrated in Technology at 23% of assets, up from 19% a quarter earlier, followed by Financials and Consumer Discretionary.
Against the trend, Arrowstreet Capital opened a new position in Edwards Lifesciences worth $127M.
- Arrowstreet Capital's largest Q4 2019 buy was Edwards Lifesciences: 1,637,208 shares worth $127M.
- Arrowstreet Capital added most to Intel in Q4 2019, an estimated $285M increase.
- Arrowstreet Capital's biggest Q4 2019 reduction was Union Pacific, cutting an estimated $329M.
- Arrowstreet Capital fully exited Celgene Corp in Q4 2019, selling an estimated $505M.
- Arrowstreet Capital's ten largest holdings make up 19% of its $43B portfolio in Q4 2019.
- Arrowstreet Capital opened 505 new positions and closed 331 in Q4 2019.
- Arrowstreet Capital's portfolio value rose 0.28% quarter-over-quarter to $43B.
Based on Arrowstreet Capital's 13F filing for Q4 2019, filed 13 Feb 2020.